If retatrutide were to receive regulatory approval in future, its pricing would likely be subject to negotiation between the manufacturer (Eli Lilly) and NHS England under the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG, 2024), as well as appraisal by the National Institute for Health and Care Excellence (NICE) to determine cost-effectiveness
MOTS-c enhances mitochondrial signaling and biogenesis
In this case, an oral dissolving tablet must not be swallowed
Multi-dose vials waste less medication than pre-filled pens when patients are titrating or using non-standard doses
Complementary mechanisms, pressure control plus neuronal protection potentially superior to either alone
Cross-reactive immunity Licensed vaccines were originally designed to target the SARS-CoV-2 Wuhan-Hu-1 strain without knowledge of how global transmission and preexisting cross-reactive infection or vaccine-induced immunity would influence viral sequence evolution